Vaxcyte, Inc. (5VA)
XMUN 
Summary
5VA Chart
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte: Financial Durability And The Case For Disruption
Vaxcyte is positioned to disrupt the pneumococcal vaccine market with its engineered VAX-31, overcoming carrier suppression limitations faced by incumbents. PCVX's $2.7B cash position supports an aggressive Phase 3 program, with a projected runway through 2028, mitigating financing and execution risks. VAX-31 targets 95% of U.S. adult IPD strains, aiming for best-in-class breadth and efficacy, with pivotal Phase 3 OPUS trial data expected in Q4 2026.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Vaxcyte, Inc. (5VA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Vaxcyte, Inc. ever had a stock split?
Vaxcyte, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Grant E. Pickering CEO | XMUN Exchange | US92243G1085 ISIN |
| US Country | 414 Employees | - Last Dividend | - Last Split | 12 Jun 2020 IPO Date |
Overview
Vaxcyte, Inc. represents a pioneering force in the field of biotechnology, focusing its considerable expertise on the development of innovative protein vaccines aimed at the prevention and treatment of bacterial infectious diseases. Born from its previous incarnation as SutroVax, Inc., the company underwent a rebranding in May 2020 to emerge as Vaxcyte, Inc., marking a new chapter in its commitment to combatting infectious diseases. Since its establishment in 2013, Vaxcyte has dedicated itself to advancing science and technology with its headquarters located in San Carlos, California. The company's approach blends cutting-edge research with clinical acumen, underscoring its ambition to address some of the most challenging bacterial pathogens through its vaccine development pipeline.
Products and Services
- VAX-24:
As Vaxcyte, Inc.'s frontrunner candidate, VAX-24 is a 24-valent investigational pneumococcal conjugate vaccine designed with the vision of preventing invasive pneumococcal disease. This vaccine exemplifies the company's dedication to innovation in vaccine technology, targeting a wide range of pneumococcal strains to offer comprehensive protection.
- VAX-31:
VAX-31 is a testament to Vaxcyte’s forward-thinking strategy, aiming to provide immunity against emerging bacterial strains and the ever-growing challenge of antibiotic resistance. This vaccine candidate is designed to extend the protective reach beyond the current vaccine offerings and address future public health needs.
- VAX-A1:
Focusing on the causative agent of severe throat infections, VAX-A1 is a novel conjugate vaccine candidate targeting Group A Streptococcus. VAX-A1 represents Vaxcyte's ambition to prevent diseases caused by this common, yet potentially dangerous, bacterium.
- VAX-PG:
Vaxcyte's innovative approach to oral health is embodied in VAX-PG, a novel protein vaccine candidate aimed at combating the keystone pathogen responsible for periodontitis. This vaccine underlines the company's commitment to expanding the scope of vaccine-preventable diseases to include oral health conditions.
- VAX-GI:
Addressing the need for vaccines against gastrointestinal infections, VAX-GI is being developed to prevent disease caused by Shigella, a bacterium responsible for significant illness globally. This vaccine candidate highlights Vaxcyte's efforts to tackle a broad spectrum of infectious agents through its diversified vaccine pipeline.
